{
    "nct_id": "NCT06824363",
    "official_title": "Proof of Principle Study Evaluating Single Dose Dual Immune Checkpoint Inhibitors to Increase Intra-tumoral T Cells in Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinomas with ARID1A Mutations: ESR-22-22082",
    "inclusion_criteria": "* Non metastatic GEC including locally advanced unresectable\n* Treatment naïve\n* Histologically proven adenocarcinoma of the esophagus or the stomach with ARID1a mutation either by liquid biopsy (ctDNA) or tissue NGS/WES\n* MSI-Stable or pMMR\n* Age ≥ 18 years\n* Body weight > 66 pounds\n* ECOG ≤ 2\n* Repeat biopsy feasible\n* No clinically significant autoimmune disease\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients with known metastatic disease\n* Prior systemic treatment for esophagus, GEJ, or the stomach adenocarcinoma\n* Patients with uncontrolled autoimmune disease per investigator discretion\n* Inability or refusal to undergo biopsy procedures to obtain tissue samples",
    "miscellaneous_criteria": ""
}